Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

(2020) A. Mantovani et al.   DIABETES & METABOLISM

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes

(2020) Lin Liu et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis

(2020) Rod S. Taylor et al.   GASTROENTEROLOGY

A diabetologist’s perspective of non‐alcoholic steatohepatitis (NASH): Knowledge gaps and future directions

(2020) Kenneth Cusi   LIVER INTERNATIONAL

Complications, morbidity and mortality of nonalcoholic fatty liver disease

(2020) Alessandro Mantovani et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity

(2020) Amedeo Lonardo et al.   Annals of Hepatology

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

(2020) Jean-François Dufour et al.   GUT

Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research

(2020) Amedeo Lonardo et al.   Journal of Clinical Medicine

Contributions of amino acid, acylcarnitine and sphingolipid profiles to type 2 diabetes risk among South-Asian Surinamese and Dutch adults

(2020) Mirthe Muilwijk et al.   BMJ Open Diabetes Research & Care

Editorial: a diabetologist's perspective on the diagnosis and monitoring of NAFLD

(2020) Giovanni Targher   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease

(2020) Jiahua Li et al.   Clinical Journal of the American Society of Nephrology

Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

(2020) Jeffrey Budd et al.   Current Diabetes Reports

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

(2020) Mohammad S. Kuchay et al.   DIABETOLOGIA

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals

(2020) Alessandro Mantovani et al.   GUT

Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors

(2020) Alexandros Sachinidis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

(2020)   DIABETES CARE

Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis

(2020) Simona Panunzi et al.   DIABETES OBESITY & METABOLISM

Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

(2020) Maria-Styliani Kalogirou et al.   Clinics and Research in Hepatology and Gastroenterology

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

(2020) Philip N. Newsome et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease

(2019) Joan Khoo et al.   LIVER INTERNATIONAL

Sex Differences in NAFLD : State of the Art and Identification of Research Gaps

(2019) Amedeo Lonardo et al.   HEPATOLOGY

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

(2019) Philip Newsome et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation

(2019) Maurice B. Bizino et al.   DIABETOLOGIA

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2019) Søren L Kristensen et al.   Lancet Diabetes & Endocrinology

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme

(2018) K. Cusi et al.   DIABETIC MEDICINE

Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement

(2018) Frédéric Brioude et al.   Nature Reviews Endocrinology

Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults

(2018) Christopher D Byrne et al.   BMJ-British Medical Journal

Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults

(2018) Christopher D Byrne et al.   BMJ-British Medical Journal

Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD

(2018) Jinhua Yan et al.   HEPATOLOGY

Non-alcoholic fatty liver disease – A global public health perspective

(2018) Zobair M. Younossi   JOURNAL OF HEPATOLOGY

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

(2018) Adrian F Hernandez et al.   LANCET

Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option

(2017) Gauri Dhir et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

(2017) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

(2017) Wenhuan Feng et al.   Journal of Diabetes

Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum

(2016) Timothy Hardy et al.   Annual Review of Pathology-Mechanisms of Disease

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

(2016) A. Dutour et al.   DIABETES OBESITY & METABOLISM

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

(2016) Giovanni Targher et al.   JOURNAL OF HEPATOLOGY

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

(2016) Matthew James Armstrong et al.   LANCET

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease

(2015) Ilkay S Idilman et al.   ACTA RADIOLOGICA

Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies

(2015) Wenjuan Tang et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups

(2015) Amedeo Lonardo et al.   DIGESTIVE AND LIVER DISEASE

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?

(2014) Nanda Gruben et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

(2014) Ning Shao et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes

(2014) Lise L Gluud et al.   BMJ Open

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

(2013) Quentin M. Anstee et al.   Nature Reviews Gastroenterology & Hepatology

Serum Levels of Acylcarnitines Are Altered in Prediabetic Conditions

(2013) Manuel Mai et al.   PLoS One

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program

(2012) M. J. Armstrong et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans

(2012) Susan Cheng et al.   CIRCULATION

Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis

(2011) Gianluca Svegliati-Baroni et al.   LIVER INTERNATIONAL

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

(2010) Nitika Arora Gupta et al.   HEPATOLOGY